Rirong Chen

Rirong Chen

Auto-generated profile, based on publicly available information

Rirong Chen

Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2023 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
RCRirong Chen
Rirong Chen
QCQia Chen
Qia Chen
JZJieqi Zheng
Jieqi Zheng
ZZZhirong Zeng
Zhirong Zeng
MCMinhu Chen
Minhu Chen
Shenghong ZhangShenghong Zhang
Shenghong Zhang
Inflammatory bowel diseases (IBD) is featured by gastrointestinal inflammation and a disease course with alternating recurrence and remission. The global burden caused by IBD has significantly boosted in recent years, necessitating treatment optimization. Serum amyloid A (SAA) is a class of 104 amino acid conservative acute-phase proteins, which is essential in immune-mediated inflammatory processes, like IBD. The SAA monomeric structure is composed of four α-helical regions and a C-terminal amorphous tail. Its disordered structure enables multiple bindings to different ligands and permits multiple functions. It has been proven that SAA has dual roles in the inflammatory process. SAA stimulates the pro-inflammatory cytokine expression and promotes the pathogenic differentiation of TH17 cells. In addition, SAA can remove toxic lipids produced during inflammatory responses and membrane debris from dead cells, redirect HDL, and recycle cholesterol for tissue repair. In IBD, SAA acts on gut epithelium barriers, induces T-cell differentiation, and promotes phagocytosis of Gram-negative bacteria. Owing to the tight connection between SAA and IBD, several clinical studies have taken SAA for a biomarker for diagnosis, assessing disease activity, and predicting prognosis in IBD. Furthermore, 5-MER peptide, a drug specifically targeting SAA, has shown anti-inflammatory effects in some SAA-dependent animal models, providing novel insights into the therapeutic targets of IBD.

10 February 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
RCRirong Chen
Rirong Chen
XPXiaobai Pang
Xiaobai Pang
LLLi Li
Li Li
ZZZhirong Zeng
Zhirong Zeng
MCMinhu Chen
Minhu Chen
Shenghong ZhangShenghong Zhang
Shenghong Zhang
The exact pathogenesis of inflammatory bowel disease (IBD), a chronic gastrointestinal inflammatory disease comprising Crohn’s disease and ulcerative colitis, remains unclear. Studies on ubiquitination, which regulates the degradation of inflammation signalling pathway molecules, and deubiquitination have provided novel insights. Targeting the ubiquitin-specific protease (USP) family of deubiquitinases elucidates IBD signalling pathway mechanisms and possibly, IBD therapeutic solutions. Here, we characterised USPs as chief regulators of pro-inflammatory signalling pathways, including nuclear factor-κB and transforming growth factor-β; analysed the relationship between USPs and IBD pathogenesis in terms of genetic susceptibility, intestinal epithelial barrier, immunity, and gut microbiota; and discussed future research prospects.

14 November 2024 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
JZJieqi Zheng
Jieqi Zheng
ZFZinan Fan
Zinan Fan
CLChao Li
Chao Li
DWDaiyue Wang
Daiyue Wang
Shenghong ZhangShenghong Zhang
Shenghong Zhang
RCRirong Chen
Rirong Chen
Objectives: Acute severe ulcerative colitis (ASUC) poses challenges to patient management owing to its high surgical rate. This study aimed to identify predictors of colectomy in patients with ASUC. Design: This is a systematic review and meta-analysis. Data sources: PubMed and Web of Science were searched up to April 2024. Eligibility criteria: Studies on the predictors of colectomy in adult patients with ASUC were eligible. Data extraction and synthesis: Two reviewers independently extracted the data using a prespecified data collection sheet. A qualitative synthesis was performed in tabular form. Random-effect meta-analyses were conducted using OR and 95% CI. Results: Forty-two studies were included in the systematic review. The reported variables can be categorised into biomarkers, auxiliary examination findings, demographic and clinical characteristics, and drug factors. Through meta-analysis, albumin (OR 0.39 (95% CI 0.26 to 0.59) per 1 g/dL increment, I2=0.0%), high C reactive protein level (2.63 (1.53 to 4.52), I2=29.6%), high erythrocyte sedimentation rate level (2.92 (1.39 to 6.14), I2=0.0%), low haemoglobin level (2.08 (1.07 to 4.07), I2=56.4%), fulfilling the Oxford criteria (4.42 (2.85 to 6.84), I2=0.0%), extensive colitis (1.85 (1.24 to 2.78), I2=47.5%), previous steroids (1.75 (1.23 to 2.50), I2=17.7%) or azathioprine (2.25 (1.28 to 3.96), I2=0.0%) use, and sarcopenia (1.90 (1.04 to 3.45), I2=0.0%) were identified as valuable predictors for colectomy within 1 year. The ulcerative colitis endoscopic index of severity (OR 2.41 (95% CI 1.72 to 3.39), I2=1.5%) was the only predictor found to predict colectomy over 1 year. Conclusion: Identification of these predictors may facilitate risk stratification of patients with ASUC, drive personalised treatment and reduce the need for colectomy.

30 December 2023 in United European Gastroenterology Journal
Verified
Journal Article
Open access
RCRirong Chen
Rirong Chen
YTYizhe Tie
Yizhe Tie
YHYongle Huang
Yongle Huang
XZXi Zhang
Xi Zhang
ZZZhirong Zeng
Zhirong Zeng
Shenghong ZhangShenghong Zhang
Shenghong Zhang
Background: Clinical remission (CR) is the principal short‐term treatment target in patients with ulcerative colitis (UC). However, whether rapidly achieving CR indicates better outcomes remains unclear.Objectives: We aimed to explore the associations between the timing of CR and therapeutic outcomes in UC.Methods: This study included UC patients from the UNIFI trial. Week‐2 CR and time to CR were the major variables of interest. Endoscopic remission (ER) at week 52 was the primary outcome. Multivariate logistic regression was performed to evaluate the association between variables and outcomes.Results: Week‐2 CR was associated with ER (aOR: 2.37 [95% CI: 1.28, 4.37], p = 0.006) and Histological remission (HR) (aOR: 2.87 [95% CI: 1.42, 5.72], p = 0.003) at week 52. Moreover, C‐reactive protein (CRP) remission could further stratify patients without CR and predict week‐52 outcomes. Patients with clinical activity + CRP remission (aOR: 0.49 [95% CI: 0.26, 0.93], p = 0.039) and clinical activity + CRP activity (aOR: 0.24 [95% CI: 0.11, 0.52], p < 0.001) had gradually decreased likelihood of achieving ER, when compared to those with CR. For time to CR, we found that the earlier to CR, the better endoscopic and histological outcomes patients would attain. Patients achieving CR at weeks 2, 4/8, 12/16 and >16 had gradually reduced proportions of ER (51.9% vs. 40.8% vs. 31.6% vs. 8.8%, p < 0.001) and HR (37.0% vs. 19.8% vs. 17.1% vs. 6.1%, p < 0.001) at week 52. Compared with week 2, achieving CR at weeks 4/8, 12/16 and >16 had 39%, 55% and 92% lower likelihoods of week‐52 ER, respectively.Conclusions: Week‐2 CR indicates better outcomes in UC patients receiving ustekinumab. Moreover, achieving CR more rapidly is associated with higher probability of ER and HR.

23 June 2023 in United European Gastroenterology Journal
Verified
Journal Article
Open access
RCRirong Chen
Rirong Chen
YTYizhe Tie
Yizhe Tie
XZXi Zhang
Xi Zhang
LLLi Li
Li Li
MCMinhu Chen
Minhu Chen
Shenghong ZhangShenghong Zhang
Shenghong Zhang
Background: Fecal lactoferrin (FL) is associated with disease activity and relapse in ulcerative colitis. However, whether FL could early predict long-term outcomes in ulcerative colitis is poorly understood. Methods: This post-hoc analysis included participants who received biologics and had available data of FL concentration at week 4 from the UNIFI and PURSUIT trials (n = 1063). Therapeutic outcomes, including clinical remission, endoscopic improvement and remission, and histological improvement and remission, were evaluated at the end of maintenance therapy. The incidence of colectomy was observed from week 0 to maximum week 228 in the PURSUIT trial (n = 667). Multivariate logistic and Cox proportional-hazard regression were conducted to evaluate the associations between FL and therapeutic outcomes and colectomy, respectively. Results: A high FL level at week 4 was associated with poor long-term clinical, endoscopic and histologic outcomes. FL >84.5 mu g/mL predicted a low likelihood of clinical (OR [95% CI]: 0.43 [0.32, 0.57]; p < 0.001), endoscopic (OR [95% CI]: 0.40 [0.29, 0.56]; p < 0.001), and histological (OR [95% CI]: 0.27 [0.14, 0.53]; p < 0.001) remission. Moreover, week-4 FL could add prognostic value to fecal calprotectin and clinical and endoscopic scores for informing long-term therapeutic outcomes. For the risk of colectomy, patients with week-4 FL = 20.1 mu g/mL had an incidence rate of 1.10% and 6.39%, respectively. Patients with FL >= 20.1 mu g/mL had a 995% higher risk of colectomy (HR [95% CI], 10.95 [1.45, 82.74]). Conclusion: FL could be a promising prognostic biomarker for long-term therapeutic outcomes and risk of colectomy in patient of ulcerative colitis.

16 December 2024 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
JZJieqi Zheng
Jieqi Zheng
XZXi Zhang
Xi Zhang
LZLiqian Zhang
Liqian Zhang
LLLi Li
Li Li
MCMinhu Chen
Minhu Chen
Shenghong ZhangShenghong Zhang
Shenghong Zhang